

NEOTHERAPEUTICS INC

Form 8-K

June 03, 2002

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934**

May 30, 2002

Date of Report (Date of earliest event reported)

NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction
of Incorporation)

**157 Technology Drive
Irvine, California**

(Address of principal executive offices) **92618**
(Zip Code)

000-28782
(Commission File Number)

93-0979187
(IRS Employer
Identification Number)

(949) 788-6700
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On May 30, 2002, NeoTherapeutics, Inc. issued a news release announcing the interim results from its pilot study of Neotrofin in patients with early-stage Parkinson's disease. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

Item 7. Exhibits

Exhibits:
99.1 Press
Release
dated
May 30,
2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: June 3, 2002

By:

Name:

Title: /s/ Samuel Gulko

Samuel Gulko

Senior Vice President

Finance,

Chief Financial Officer,

Secretary and Treasurer

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

Exhibit
Number

99.1 Press Release dated
May 30, 2002.

Document Description